Ligand validation:2I21

LI1: 1-[2,6,10.14-TETRAMETHYL-HEXADECAN-16-YL]-2-[2,10,14-TRIMETHYLHEXADECAN-16-YL]GLYCEROL

LI1 is a Ligand Of Interest in 2I21 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2I21_LI1_A_607	18%	45%	0.147	0.763	1.04	1.08	2	3	3	0	84%	0.8444
2I21_LI1_A_613	17%	62%	0.155	0.856	0.45	0.98	-	1	0	1	29%	0.2889
2I21_LI1_A_606	14%	66%	0.153	0.851	0.48	0.82	-	-	1	0	18%	17.78
2I21_LI1_A_612	10%	43%	0.224	0.842	1.07	1.14	1	1	3	0	40%	0.4
2I21_LI1_A_601	9%	39%	0.207	0.755	1.11	1.27	2	4	3	2	71%	0.7111
2I21_LI1_A_602	9%	10%	0.224	0.728	1.05	3.24	2	9	10	0	91%	0.9111
2I21_LI1_A_608	8%	40%	0.204	0.785	1.07	1.28	1	3	1	0	40%	0.4
2I21_LI1_A_603	4%	42%	0.22	0.715	1.1	1.15	1	1	5	0	40%	0.4
2I21_LI1_A_604	2%	43%	0.223	0.627	1.11	1.09	1	1	0	0	36%	0.3556
2I21_LI1_A_609	1%	40%	0.331	0.651	1.15	1.17	1	2	0	0	36%	0.3556
2I21_LI1_A_611	1%	20%	0.381	0.685	1.15	2.22	1	4	6	2	38%	0.3778
2I21_LI1_A_610	1%	44%	0.346	0.523	1.04	1.11	2	2	7	0	89%	0.8889
2I21_LI1_A_605	0%	73%	0.353	0.204	0.45	0.6	-	-	0	0	18%	17.78
3T45_LI1_B_604	36%	62%	0.142	0.852	0.6	0.85	-	1	3	0	89%	0.8889
2I20_LI1_A_613	34%	60%	0.121	0.929	0.48	1.04	-	1	0	1	29%	0.2889
3NSB_LI1_A_1008	26%	77%	0.097	0.897	0.3	0.6	-	-	0	0	11%	11.110000000000001
4X32_LI1_A_303	24%	89%	0.135	0.9	0.4	0.25	-	-	0	0	22%	0.2222
6RQP_LI1_A_502	23%	64%	0.134	0.905	0.66	0.71	-	-	2	0	18%	17.78
1S8J_LI1_A_605	20%	68%	0.156	0.908	0.49	0.75	-	-	0	0	18%	17.78

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.